Health Care · Wholesale-Drugs, Proprietaries & Druggists' Sundries

HLF HERBALIFE LTD. SEC Filings & Insider Trading Activity 2026

company
CIK 1180262116 filings
Russell 2000

HLF at a glance

HERBALIFE LTD. (HLF, SEC CIK 1180262) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), HERBALIFE LTD. (HLF) reported revenue of $5.0 billion (up 0.9% from FY2024) and net income of $228.3 million. Diluted EPS was $2.20.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding HERBALIFE LTD. (HLF) shares worth $609.0 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by L'Helias Sophie on June 4, 2026 of 1,200 shares at $11.31 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$5.0B
+0.9% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
28 funds
$609.0M · −2 vs prior quarter
Latest 8-K
Nov 2, 2026
Item 2.02 · Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Global health and wellness company using direct-selling model with independent Members distributing nutrition and lifestyle products in 95 markets
  • New products: Launched HL/Skin skincare line in Europe/Africa, Protein Gelato in Brazil, MultiBurn metabolic supplement and Life I/O™ healthy lifespan brand in North America
  • Strategic shift: Expanded targeted "daily consumption" models like Nutrition Clubs and Member-led wellness programs to increase customer engagement and loyalty
  • Quantitative metric: 6.4 million total Members worldwide with approx. 750,000 sales leaders as of Dec 31, 2025; 70.3% sales leader retention rate for 2026 re-qualification
  • Noteworthy fact: Unique China business model employing independent service providers due to regulatory restrictions on multi-level marketing, with tailored compensation system

Risk Factors

  • Regulatory risk: Compliance with FTC Consent Order, failure could materially harm business and financial results
  • Geopolitical risk: China market requires modified business model amid political and legal uncertainties
  • Supply chain risk: Dependence on manufacturing facilities and third-party suppliers for quality and timely product supply
  • Competitive risk: Competition from more resourceful direct-selling organizations and emerging weight management drug technologies
  • Financial risk: Obligations under convertible notes could dilute shares and depress share price upon conversion

Management Discussion & Analysis

  • Revenue $5,037.5M, up 0.9% YoY (+$44.4M); local currency sales up 2.5%
  • Operating margin 9.6% in 2025 vs 7.7% in 2024; net income $228.3M, down 10.2% YoY due to $132.2M higher income taxes
  • Best segment: Primary Reporting Segment net sales $4,758.4M (+1.3%), contribution margin 42.8%; worst: China net sales down 6.2% to $279.1M, contribution margin +1.6%
  • No explicit cash flow or capital allocation $ disclosed in excerpt; prior year included $10.5M loss on debt extinguishment
  • Management outlook highlights ongoing inflation, FX risk, geopolitical conflicts impacting costs/pricing; focus on Member tools, new product launches, and digital platform rollout (Pro2col) in 2026

AI summary of the HLF 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors disclosed in the 2025 10-K and Q2 10-Q
  • Carried-forward risks cover business, reputation, prospects, financial condition, operating results, cash flows, liquidity, and share price
  • No newly triggered regulatory, legal, operational, competitive, market, or financial risk identified

Management Discussion & Analysis

  • Quarterly revenue $1,350.2M, up 6.0% from $1,273.7M YoY
  • Operating margin 10.3% vs 9.9% YoY, net margin 4.2% vs 3.4%
  • Best category Energy, Sports, and Fitness: $180.8M, up 13.9%; worst Literature, Promotional, and Other: $17.4M, down 12.6%
  • Cash $409.2M; nine-month operating cash flow $298.0M vs $235.0M; capital expenditures $40.3M
  • Outlook: $55M-$65M 2026 capital expenditures; headwinds from inflation, tariffs, energy costs, foreign exchange and geopolitical conflicts

AI summary of the HLF 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 2, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for quarter ended September 30, 2026
  • Financial details and management commentary available in Exhibit 99.1 press release

Item 7.01: Regulation FD Disclosure

  • Investor slides support Herbalife’s earnings call for Q3 fiscal 2026, ended September 30, 2026
  • Presentation availability signals supplemental management commentary for investors

Item EX-99.1: Item EX-99.1

  • Q3 net sales $1.35B, up 6.0%, marking the fifth consecutive quarter of reported and constant-currency growth
  • Adjusted EBITDA $182.4M, margin 13.5%, up 70 basis points, while FX created approximately $11.3M of headwind
Filed Aug 31, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Stephan Gratziani transitioning from Chief Executive Officer effective October 31, 2026
  • CEO succession creates near-term leadership uncertainty for strategy and operating execution
Filed Aug 5, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CFO John DeSimone retiring December 31, 2026, creating a planned finance leadership transition
  • Scott Schaefer becoming CFO January 1, 2027, after serving as Senior Vice President, Finance and Transformation since November 2025

Item EX-99.1: Item EX-99.1

  • Q2 net sales $1.327B, up 5.4% YoY, marking the fourth consecutive quarter of reported growth
  • Adjusted EBITDA $166.6M, while GAAP net loss $(26.3)M reflected a $94.6M debt-extinguishment charge

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results for the quarter ended June 30, 2026 announced on August 5, 2026
  • Full financial results and management commentary available in Exhibit 99.1, the attached earnings release

Item 7.01: Regulation FD Disclosure

  • Investor slides support Herbalife’s earnings call for Q2 fiscal 2026 ended June 30, 2026
  • Presentation availability directs investors to the company’s investor-relations website under “IR Calendar”

AI summaries of HLF 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for HLF

Don't miss the next HLF filing

  • Alerts as it files. A push when HLF files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut HLF, by share count.
  • Ask anything. An AI agent that reads every HLF filing and answers with sources.

HLF alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Schaefer Scott StephenANov 4, 2026-
DeSimone JohnANov 4, 2026-
Lamberti FrankFAug 4, 2026$12.80
L'Helias SophieBuyJun 4, 2026$11.31
Hicks TroySellMay 19, 2026$12.32
Hicks TroyFMay 18, 2026$12.59
Hicks TroyMMay 18, 2026-
Hicks TroyFMay 18, 2026$12.59

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$5.0B$5.0B
Gross Profit-$3.9B$3.9B
Operating Income-$385.9M$481.0M
Net Income-$254.3M$228.3M
Gross Margin-77.9%77.9%
Op. Margin-7.7%9.5%
Net Margin-5.1%4.5%
Balance Sheet
Total Assets$2.8B$2.7B$2.8B
Equity-$1.1B-$801.1M-$515.1M
ROE--31.7%-44.3%
Per Share
EPS-$2.50$2.20
Cash Flow
Operating CF-$285.4M$333.3M
CapEx-$122.0M$80.4M

Source: XBRL data in HERBALIFE LTD. (HLF)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate HLF share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
HLF shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$609.0M
Q2 202630$674.1M
Q1 202631$811.9M
Q4 202527$752.5M
Q3 202527$461.8M
Q2 202528$464.1M
Q1 202526$398.3M
Q4 202422$241.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 219 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

HLF filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 6, 2026--
4Nov 6, 2026--
10-QNov 2, 2026Analysis
8-KNov 2, 2026Analysis-
8-KAug 31, 2026Analysis-
8-KAug 5, 2026Analysis-
4Aug 5, 2026--
10-QAug 5, 2026Analysis
4Jun 4, 2026-
4May 20, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
SC 13GMay 6, 2026-
10-QMay 6, 2026Analysis
8-KMay 6, 2026Analysis
4May 5, 2026-

Related Health Care companies

All Health Care →

HLF SEC filings: frequently asked questions

Which institutions hold HLF stock?

As of September 30, 2026, the largest HERBALIFE LTD. (HLF) holders among the 13F filers tracked by SignalX were Baupost Group ($124.5 million), BlackRock ($102.0 million), Vanguard Portfolio Management LLC ($73.6 million), Renaissance Technologies LLC ($55.5 million), Vanguard Capital Management LLC ($53.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was HLF's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), HERBALIFE LTD. (HLF) reported revenue of $5.0 billion (up 0.9% from FY2024) and net income of $228.3 million. Diluted EPS was $2.20. The figures come from the XBRL data in the 10-K.

What are the main risks in HLF's latest 10-K?

In the 10-K filed February 18, 2026, HERBALIFE LTD. (HLF) flagged: Regulatory risk: Compliance with FTC Consent Order, failure could materially harm business and financial results. Geopolitical risk: China market requires modified business model amid political and legal uncertainties. (AI summary of the Risk Factors section.)

What did HLF report in its latest 8-K?

HERBALIFE LTD. (HLF) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 fiscal 2026 results announced for quarter ended September 30, 2026.

What are the latest HLF SEC filings?

HERBALIFE LTD. (HLF) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 6, 2026.

What is HLF's SEC CIK number?

HERBALIFE LTD. (HLF)'s SEC Central Index Key (CIK) is 1180262. EDGAR lists every HLF filing under that number.

Ask anything about HLF

The research agent reads HLF's filings, financials, insider trades and 13F holders, then answers with sources.